Patent Drafting for Multiple Jurisdictions

Dr. Murphy focuses her practice on client counseling and patent prosecution for a range of clients. She prepares new patent applications, prosecutes U.S. and foreign applications, and represents applicants at appeals and oral hearings before the PTAB. She has experience in prosecuting inter partes and ex partes reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.

Dr. Yang focuses on complex patent litigation before U.S. district courts and inter partes review (IPR) proceedings in the chemical, pharmaceutical, and biotechnological fields. She has experience representing pharmaceutical patent holders in Hatch-Waxman litigations and has drafted numerous appellant and appellee briefs for pharmaceutical clients at the U.S. Court of Appeals for the Federal Circuit. She has handled various aspects of trial preparation, including fact and expert discovery, depositions of key witnesses and experts, and motion practice, along with other pre-litigation due diligence and position analysis. She also has worked on multiple IPR cases on behalf of petitioners or patent owners and has been involved in all aspects of those cases. In addition, she has conducted a variety of due diligence analysis in the biotechnological field for licensing, acquisition, freedom-to-operate, and startup fundraising.

Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.

Ms. Kim focuses on patent litigation and patent prosecution in the chemical and pharmaceutical fields. Her litigation experience includes conducting discovery on Abbreviated New Drug Application (ANDA) litigation. She has also researched various legal matters in preparation of inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.

Mr. Barcombe is a qualified European and Chartered (UK) patent attorney with a background in biotechnology. His experience extends to drafting, prosecuting and opposing European patent applications directed to a wide array of technologies, including nucleotide therapies, stem cells and biomarkers. Prior to joining the firm, Mr. Barcombe worked for another large patent law firm in the U.K. He is adept in patent drafting, prosecution, and opposition, and providing strategic advice to clients ranging from global pharmaceutical companies to startups. Mr. Barcombe has experience managing international portfolios for clinical and pre-clinical candidates and pursuing protection for the candidates themselves in addition to their medical uses, manufacturing methods, and patient subgroups. His technical expertise spans the life sciences, covering biologics, biotechnology, clean energy, food and beverage, textiles and pharmaceuticals. Mr. Barcombe previously worked in research and development for a multinational pharmaceutical company and practiced intellectual property management for a world-leading animal health institute, as well as conducted academic research investigating the delivery of therapeutic nucleotides.